Willow Biosciences Inc.

Equities

WLLW

CA97111B4047

Pharmaceuticals

End-of-day quote Toronto S.E. 06:00:00 2024-04-17 pm EDT 5-day change 1st Jan Change
0.09 CAD +5.88% Intraday chart for Willow Biosciences Inc. 0.00% -10.00%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Willow Biosciences Narrows 2023 Loss YOY MT
Willow Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Willow Biosciences Announces Second Strategic Investment From Kalsec MT
Willow Biosciences Secures Strategic Investment From Kalsec to Develop Natural Food Ingredient MT
Willow Biosciences Inc. announced that it expects to receive funding from Kalsec Inc. CI
Willow Biosciences Enters Partnership With Global Ingredient Manufacturer MT
Willow Biosciences Inc. Announces Collaboration with Global Active Pharmaceutical Ingredient Manufacturer to Develop A More Sustainable, Cost-Effective Manufacturing Process for A Large Volume Global Market CI
Willow Biosciences Announces Collaboration with Active Pharmaceutical Ingredient Manufacturer to Manufacture More Sustainable, Cost-Effective Manufacturing Route for Their Largest Product Sold Globally CI
Willow Biosciences Announces Collaboration With Enterin MT
Willow Biosciences Inc. Announces Collaboration with Enterin, Inc. to Develop Sustainable Interimates and Active Pharmaceutical Ingredients CI
Willow Biosciences Highlights Growth Plans for 2024, Provides 2023 Highlights MT
Willow Biosciences Brief: Says Plans For "Significant" Growth In 2024 MT
Toronto Stocks Flat; Laurentian Bank of Canada Declines on Lower 4Q Profit, Revenue DJ
Willow Biosciences and Nasdaq-listed Biopharma Co Advancing Development Program MT
Willow Biosciences Brief: Willow and a Nasdaq-listed biopharma company Advancing Development Program MT
Willow Biosciences Reports Q3 Results, Provides Update MT
North American Morning Briefing : Stocks Seen -2- DJ
Willow Biosciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Aurora Cannabis Announcing Settlement of Patent Litigation MT
Willow Biosciences Inc. announced that it has received CAD 0.8 million in funding CI
Willow Biosciences and Suanfarma Detail Collaboration MT
Willow Biosciences Inc. and Suanfarma Announce Collaboration on Development of Large Volume Anti-Infective API Through Precision Fermentation CI
Willow Biosciences Announced Company Insider Led Convertible Debenture Financing MT
Willow Biosciences Inc. announced that it expects to receive CAD 1.2 million in funding CI
Willow Biosciences Announced Completion of R&D Program on Cost Effective, Sustainably Produced UDCA MT
Chart Willow Biosciences Inc.
More charts
Willow Biosciences Inc. is a Canada-based biotechnology company. The Company develops and produces precision fermented functional ingredients for the health and wellness, food and beverage and personal care markets. Its FutureGrown biotechnology platform allows production with sustainability at its core. Its commercial product, Cannabigerol CBG, which is a cannabinoid that has anti-microbial, anti-inflammatory, and antioxidant properties. It also offers BioOxi, a bio-oxidation technology platform. By leveraging BioOxi, commercial partners can revolutionize manufacturing of oxygenated and hydroxylated functional ingredients, such as steroids, polyphenols, oxyterpenes and certain other targeted ingredients produced from such methods. It is also developing BioOxi-based process for production of the generic active pharmaceutical ingredient (API), hydrocortisone, and its derivatives. Its other pipeline products include Ursodeoxycholic acid (UCAC), Astaxanthin, B-carotene and others.
More about the company
  1. Stock Market
  2. Equities
  3. WLLW Stock
  4. News Willow Biosciences Inc.
  5. Willow Biosciences Reports Q3 EPS of $0.03